Inhibition of the MEK/ERK pathway augments nab-paclitaxel-based chemotherapy effects in preclinical models of pancreatic cancer.

Oncotarget · 2018 · PMC5797049 · PMID 29435178

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In subcutaneous xenografts of two aggressive KRAS -mutant cell lines, AsPC-1 and Panc-1, we determined that trametinib not only inhibited tumor growth as a monotherapy, but it also demonstrated a trend for an additive effect in combination with chemotherapy regimens, although it did not reach statistical significance (Figures 1 , 2 ).

also in 111,027 other papers

showed a trendno p-value reported

The addition of trametinib to chemotherapy regimens showed a trend for an additive effect on tumor growth inhibition in subcutaneous AsPC-1 and Panc-1 PDAC xenografts.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.